Contribute Try STAT+ Today

Biogen added more than $4 billion in market value on Monday after a rival Alzheimer’s disease treatment from Eli Lilly showed promise in a small clinical trial.

The preliminary benefit of Lilly’s treatment, which works similarly to Biogen’s controversial aducanumab, “adds momentum and belief” to the idea that targeting a toxic brain plaque called amyloid can slow the cognitive decline associated with Alzheimer’s, Biogen CEO Michel Vounatsos said at the J.P. Morgan Healthcare Conference. That theory, dubbed the amyloid hypothesis, had reached a scientific nadir in recent years after a string of similar medicines failed to benefit patients in key clinical trials.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.